SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

25 Jul 2019 07:00

RNS Number : 6379G
Victrex PLC
25 July 2019
 
 

 

 

 

25 July 2019

Victrex plc: Interim Management Statement

'Aero, Energy & Medical growth offset by continued Auto & Electronics weakness'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2019.

Against very strong comparatives in the Industrial division, the Group saw good growth in Aerospace and Energy, whilst in Medical, we continued to see steady growth. In line with macro-indicators and reflecting wider market performance, Automotive, Electronics and Value-Added-Resellers saw some deterioration during Q3.

 

Q3 also saw the final quarterly comparative from the large Consumer Electronics order, with no volumes sold during Q3 2019.

 

Overall, Q3 Group sales volume was down 21% to 912 tonnes (Q3 2018: 1,161 tonnes), with Group revenue down 14% to £72.0m (Q3 2018: £84.0m). Excluding the large Consumer Electronics order, Q3 Group volume was down 18% and Q3 Group revenue was down 12%. Year to date (to the end of Q3) Group sales volume of 2,811 tonnes is 18% down on the prior year (2018 YTD: 3,417 tonnes), with year to date Group revenue (to the end of Q3) of £217.8m down 13% (2018 YTD: £250.6m).

Mega-programme progress

As part of its Polymer & Parts strategy, Victrex continues to focus on delivering further milestones in its growth pipeline and mega-programmes.

 

The Group has now successfully secured the contract from a major US Automotive manufacturer for a supply of PEEK Gears commencing in FY 2020, building on the existing supply to a major European Automotive manufacturer, with over 10 other development programmes also in place.

 

In Aerospace, following completion of the US manufacturing facility which will support our Loaded Brackets and composite parts, the first prototype parts have now been supplied and we also received our first commercial volume order. In Medical, sales of our PEEK-OPTIMA™ HA Enhanced product continue to track above last year, whilst patient recruitment for the PEEK Knee clinical trial has started, with potential for the first implant before the end of our financial year.

 

Financial position and currency

Victrex has seen no material change to its financial position since 31 March 2019. Currency remains broadly neutral for the second half year, with a small tailwind for FY 2020 based on current rates and with nearly 50% of currency hedges in place.

 

Outlook

With continued weakness in Automotive and Electronics, we remain cautious on these markets, in line with the latest macro-indicators. Whilst we do not expect a recovery in these markets during the final quarter, our own sales and innovation activity, together with slightly better comparatives, offers the opportunity to deliver a more stable performance for the remainder of our financial year.

 

Victrex remains in a good position for the medium to longer term. Through our Polymer & Parts strategy we have the opportunity to drive growth in our core business, further increase our differentiation through our strong pipeline of new products and deliver attractive returns to shareholders. 

 

Analyst & investor conference call

A conference call for analysts & investors will be held today, Thursday 25 July, at 08.00am BST.

Dial in details: +44 (0) 3333 000804 PIN: 82241272#

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Communications +44 (0) 7809 595831

Richard Armitage, Chief Financial Officer +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTRIMRTMBITBPL
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.